Background
Chronic hepatitis B virus (HBV) infection is a major public health problem worldwide. An estimated 240 million people have chronic HBV infections [
1], and about 75% of them reside in the Asia-Pacific region [
2]. HBV infection causes more than one million deaths every year due to acute or chronic outcomes, including end-stage liver disease, cirrhosis, and hepatocellular carcinoma (HCC) [
3,
4]. Therefore, more aggressive antiviral therapies are needed to manage and control it.
In recent decades, regulatory agencies have approved several antiviral agents for HBV infections treatment, including interferon and several oral drugs (such as telbivudine [LdT], lamivudine [LAM], tenofovir [TDF], entecavir, and adefovir [ADV]) [
5‐
7]. Among the oral antiviral agents, several major guidelines for chronic hepatitis B recommended entecavir and tenofovir as first-line therapy for CHB [
3,
8,
9]. However, tenofovir is not available but entecavir is not affordable in some low-income countries, which limited the first-line therapy options for many patients. In recent years, with the listing of tenofovir, the price of entecavir in China has dropped significantly.
LdT is a β-L-nucleoside analog which is chose to treat patients with chronic HBV infections who have active viral replication and abnormal levels of ALT. LdT has better efficacy than lamivudine and has a higher HBeAg seroconversion rate in HBeAg-postive HBV patients compared with other oral antiviral agents [
10]. ,However, there has few researches regarding the efficacy of LdT in HBV patients with HBeAg-negative. This study evaluated the safety and efficacy of LdT -Based Optimization Strategy in patients with HBV who were HBeAg-negative.
Methods
Study design
This was a prospective, 104-week, multicenter, single-arm, open-label, phase IV, long-term trial that enrolled 154 patients from April 2012 to July 2014 among three hospitals in Guangdong Province, China (The Third Affiliated Hospital of Sun-Yet-Sen University, Guangdong General Hospital, and The Eighth People’s Hospital of Guangzhou). All enrolled patients received sequential therapy with supportive care during the whole study. Each patient received single oral tablet of LdT (600 mg) daily for the first 24 weeks. ADV was added if HBV DNA remained detectable at week 24, otherwise LdT was maintained to use until 104 weeks. Patients received LDT monotherapy with virological breakthrough were added with adefovir, otherwise TDF was chose as rescue treatment. Clinical, laboratory, and adverse event assessments were collected every 12 or 16 weeks from baseline (week 0) to week 104. This study conformed to the ethics principles of the Declaration of Helsinki and Good Clinical Practice and according to the regulatory requirements of China. It also obtained ethical approval from the Institutional Review Board (IRB) of the Third Affiliated Hospital of Sun-Yat-Sen University, IRB of Guangdong General Hospital and IRB of the Eighth People’s Hospital of Guangzhou. Written informed consent have been obtained from all participants. This study was registered in clinicaltrials.gov on January 31, 2012 and the ID No. was NCT01521975.
Inclusion and exclusion criteria
Inclusion criteria: (1) patients had HBeAg-negative CHB; (2) patients aged 18–65 years-old; (3) patients had detectable HBV S-antigen (HBsAg) at screening visit, with serum HBV-DNA level above 4 log10 IU/mL; (4) patients had ALT level at 2 to 10-fold above the upper limit than normal (ULN) of 35 U/L; (5) patients had ALT level at less than 10-fold ULN if they were complicated with liver cirrhosis. Exclusion criteria: (1) patients had coinfection with hepatitis C virus, hepatitis D virus, or HIV, decompensated liver cirrhosis or HCC; (2) patients received nucleoside analogs, immunosuppressive drugs, or other antiviral drugs; (3) patients had history of tumor.
Index detection
HBV m quantitative time resolved fluorescence diagnostic kit was provided by Suzhou Xinbo Biotechnology Co., Ltd. (Suzhou, China) and analyzed by 1235 automatic time-resolved fluoroimmunoassay system (American PE company). HBV DNA quantitative detection kit was provided by Sun Yat sen University Da’an gene Co., Ltd. (Guangzhou, China) and analyzed by Gene-Amp5700 fluorescent PCR detector (American PE company). Serum CK, creatine kinase, ULN, ALT and eGFR were detected by automatic biochemical analyzer with commercial kits (Nanjing Jiangcheng Bioengineering Institute, Nanjing, China).
Efficacy assessment
The primary endpoint was undetectable HBV-DNA (< 20 IU/mL) at week 52 and 104. The secondary endpoint was ALT normalization at week 24, 52, and 104 and loss of HBsAg seroconversion at week 52 and 104. Virological breakthrough was also recorded.
Safety assessment
The safety assessment consisted of adverse events (AEs) monitoring from clinical and laboratory examinations and their relationships with this study, based on the investigators’ assessment. The safety population included all patients who received at least one dose of the study medication (intention to treat [ITT] population) and had at least one post-baseline safety assessment.
Statistical analysis
All statistical analyses were performed using SPSS (SPSS Statistics Version 19, IBM). Continuous variables were described as means and standard deviations (SD) and categorical variables (e.g. age and gender) as number and percentages. Significant differences between groups were evaluated using one-way analysis of variance. Differences between groups were considered statistically significant at P < 0.05.
Discussion
Many major guidelines for liver diseases, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for Study of the Liver (EASL), only recommend entecavir or tenofovir as first-line therapy for treatment patients with HBV [
3]. However, many patients from the Asia-Pacific region do not have access to these drugs forced by money. Thus, lamivudine, LdT, and adefovir are still widely used in treatment of HBV.
The GLOBE study indicated that LdT had better efficacy than lamivudine in terms of virological response, serologic response, and drug resistance in CHB patients with HBeAg-positive [
11,
12]. After treatment for 2 years in GLOBE study, 82% of patients had non-detectable viremia. After 104 weeks of LdT-based optimizedd strategy, our population had a higher response rate (94%), although the research illustrated that response to entacavir was even greater (96.5%) [
13]. As a potent antiviral agent, LdT has proven efficacy in suppressing HBV replication, and has advantage in HBeAg seroconversion over other antiviral agents in HBeAg-positive patients with CHB [
14]. However, few studies have examined the effect of LdT in HBeAg-negative patients with CHB. Our results showed that LdT-based optimization strategy was effective, and 80% of patients turned to normal ALT levels and 94% patients became to undetectable HBV-DNA at week-104.
A major concern regarding LdT therapy had high rate of resistance. Liaw, et al. reported the overall resistance rate was 25.1% after 2 years of LdT treatment for CHB patients [
12], and the resistance rate was 10.8% for HBeAg-negative patients. Combination therapy might reduce drug resistance. Liu, et al. reported the incidence of drug resistance was 4% by using LdT plus ADV at week 48, 5.3% at week 96, 10% at week 144, and 11.6% at week 192 for HBeAg-positive patients with CHB [
15]. In order to decrease the resistance rate, we utilized a Roadmap strategy. The 2-year drug resistance rate was 5.6% in our trial, much lower than the related research conclusions. We found that the accumulative incidence of drug resistance might increase with treatment duration, so more long-term data are needed in the future.
Another concern biomarker is CK elevation during LdT therapy, which have been reported in many previous studies [
16,
17]. Chen, et al. studied 527 CHB patients and reported that 60.91% of them had CK elevation [
18], which was similar with our result (55%). Few studies have reported the management and prognosis of CHB patients who had CK elevation in Grade 3/4 during LdT treatment, especially those who continued with this therapy. Our results reassuringly showed that when such patients continue LdT therapy, their CK levels would gradually normalize. Very few of our patients had musculoskeletal symptoms. These results implied that patients with CK elevation in Grade 3/4 might safely in continuous LdT therapy under monitoring closely.
HBsAg loss or seroconversion often leads to cessation of nucleoside treatment [
3], and there contains special relationship of HBV genotypes and the rate of spontaneous or antiviral therapy-associated HBeAg seroconversion. For example, genotype C patients endure delayed HBeAg seroconversion and thus have a longer duration of high viral load than genotype B patients. Therefore, genotype C patients are correspondingly more prone to develop advanced fibrosis, cirrhosis and HCC than genotype B patients. And the presence of HBV mutants, such as precore and basal core promoter mutations, may affect the response to antiviral therapy in HBeAg-positive disease. Many studies demonstrated that HBsAg decreasing was related to better antiviral therapy outcome [
19]. Our study showed that LdT-based optimization strategy could decrease the HBsAg level though no patients had loss of HBsAg. The duration of treatment in our study was only 2 years, so continued monitoring of the dynamics of HBsAg was necessary for longer treatment. Meanwhile, several biomarkers predicting HBeAg seroconversion have been identified. Such as the baseline total anti-HBc levels could predict HBeAg seroconversion in HBeAg-positive CHB patients receiving antiviral therapy [
20,
21]. In addition, host genetic polymorphisms have been reported to predict response to pegylated interferon in HBeAg-positive patients [
22]. And recent clinical trials revealed that patients receiving pegylated interferon combined or add-on nucleos(t)ide analogue had significantly higher HBeAg seroconversion rates than those receiving nucleos(t)ide analogue monotherapy [
23,
24].
The quantitative detection of HBV serum markers and HBV DNA plays a complementary role in the diagnosis of HBV infection, which makes the diagnosis more accurate. It has been found that il-12a rs568408 is related to the seroconversion of Entecavir in the treatment of HBeAg. Recent studies have shown that IL-21 could promote the activation of various immune cell functions in the process of HBV infection. IL-21 gene polymorphism was related to HBV susceptibility. In addition, IL-21 expression was closely related to HBV genotype, HBV clearance, HBeAg seroconversion, HBV related cirrhosis, liver failure, liver cancer and autoimmune dieases. CHB can lead to chronic kidney disease, because of the accumulation of immune compounds in kidney. Gane, et al. found that LdT might increase eGFR by 8.5% for 4–6 years, and this effect was unrelated to its antiviral action [
25], implying a direct influence of LdT to renal function. Our study also showed that LdT therapy improved eGFR. Thus, LdT might become a good treatment option for CHB patients, especially those with high risk of developing chronic kidney disease (i.e. those with high blood pressure or diabetes),.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.